Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

STMA Fines Three Domestic E-Cigarette Brands Nearly $700,000 for Selling Products Inconsistent with Pre-Market Review

Nov.13.2024
STMA Fines Three Domestic E-Cigarette Brands Nearly $700,000 for Selling Products Inconsistent with Pre-Market Review
STMA has fined three Chinese e-cigarette brands—Mirui, Boulder, and Mevol—nearly $700,000 for selling products that were inconsistent with the information submitted during their pre-market approval process. This move underscores the STMA’s commitment to maintaining order in the domestic market and combating illegal products.

On November 7, 2024, China’s State Tobacco Monopoly Administration (STMA) announced fines totaling nearly $700,000 for three Chinese e-cigarette brands—Mirui, Boulder, and Mevol—for selling products that were inconsistent with the details provided during their pre-market review.

 

Since May 1, 2022, the STMA has enforced the Measures for the Administration of E-cigarettes, which explicitly stipulate in Article 19 that e-cigarette products that have not passed technical reviews are prohibited from being marketed or sold. Additionally, the information provided for products on the market must align with the approved details submitted during the review process.

 

However, the three licensed Chinese e-cigarette brands were found to have sold products that deviated from their approved formulas and contained unauthorized substances. As a result, the STMA imposed fines and penalties to emphasize the importance of complying with these regulations. This action also reflects the STMA’s commitment to maintaining market order and preventing the distribution of illegal products.

 

Here are the details of the three enforcement cases:

 

 

1. Zhejiang Mirui : Fined $140,000 for Unauthorized Ingredients 

 

 

Zhejiang Mirui Electronic Technology Co., Ltd. was found to have added unauthorized substances to its e-cigarette products, causing them to deviate from the approved formulas and the details submitted during the technical review process.

 

As a result, the sale of non-compliant e-cigarettes was deemed illegal. The company was ordered to cease sales of the affected products, pay a fine of approximately $140,000, and forfeit any illegal profits.

 

 

2. Shenzhen Boulder: Fined $440,000 and Suspended for Non-Compliance

 

 

Boulder (Shenzhen) Technology Co., Ltd. was penalized for adding unauthorized ingredients to its products, causing discrepancies between the products and their approved formulas. This deviation resulted in the sale of non-compliant e-cigarettes.

 

Additionally, Boulder lacked the necessary license to produce e-liquids but continued to manufacture and export them. As a result, the company was fined nearly $440,000, ordered to cease sales of non-compliant products, and suspended from operations for two months.

 

 

3. Shenzhen Mevol: Fined $112,000 for Non-Compliant Sales

 

 

Shenzhen Mevol Chuangxin Technology Co., Ltd. was found to have knowingly continued to sell e-cigarette products that did not match the approved formulas. Despite being aware that some products were inconsistent with the information provided during the technical review process, the company continued to market them.

 

This resulted in the sale of non-compliant e-cigarettes. The STMA imposed a fine of nearly $112,000, ordered the cessation of sales, and required the destruction of the non-compliant products.

 

Also Read:
[1] China Tobacco and International Tobacco Firms Exchange Briefing (Oct. 2024)
[2] Two scientific papers from China Tobacco Hunan IC were selected for the 77th Tobacco Science Research Conference (TSRC)
[3] State Tobacco Monopoly Administration Releases Typical Cases of E-Cigarette Law Enforcement
[4] State Tobacco Monopoly Administration E-cigarette Trading Management Regulations Communication
#E-cigarettes#Asia#China#Regulation
INTER-TABAC
INTER-TABAC
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International announced that the U.S. FDA has accepted the Abbreviated New Drug Application (ANDA) for its Breo® Ellipta® 100/25 generic drug, submitted by its wholly-owned subsidiary, Transpire Bio. Transpire Bio stated that if approved, it is expected to receive 180 days of market exclusivity. In the United States, Breo® Ellipta® is already approved for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD).
Sep.25 by 2FIRSTS.ai
Smoore's 2025 first-half performance: Revenue rose 18.3% to 6.013 billion yuan, with self - brand revenue up 14.1% to 1.274 billion yuan
Smoore's 2025 first-half performance: Revenue rose 18.3% to 6.013 billion yuan, with self - brand revenue up 14.1% to 1.274 billion yuan
In the first half of 2025, Smoore's revenue reached 6.013 billion yuan, up by 18.3%. The adjusted net profit was 737 million yuan, down by 2.1%. The ToB business revenue was 4.739 billion yuan, up by 19.5%, while the self - brand business revenue was 1.274 billion yuan, up by 14.1%.
Aug.21 by 2FIRSTS.ai
Research Abstract｜Months After Flavored Tobacco Ban, More Than Half of Vape Shops in California Remain Noncompliant
Research Abstract｜Months After Flavored Tobacco Ban, More Than Half of Vape Shops in California Remain Noncompliant
The study evaluated early compliance with California’s flavored tobacco sales ban (SB 793). Between April and July 2023, the research team conducted field observations at 400 vape retailers, focusing on the availability of flavored disposable e-cigarettes and JUUL pods. Results showed that about 50.3% of stores were still selling flavored products in violation of the ban, including 53.2% of disposable vape retailers and 30.9% of JUUL pod retailers.
Sep.01 by 2FIRSTS.ai
Company | Philip Morris CEO: Expected profit growth in 2025 will be the highest in over a decade, with ZYN US retail sales up 32%
Company | Philip Morris CEO: Expected profit growth in 2025 will be the highest in over a decade, with ZYN US retail sales up 32%
At the 2025 Barclays Global Consumer Conference, Philip Morris International's CEO said that strong summer sales of IQOS and ZYN will boost the company's full-year 2025 adjusted EPS by 13% to 15%, the best performance since 2011 (excluding pandemic recovery). He also noted that IQOS has maintained strong growth in Q3, with ZYN sales up about 32% in the first eight weeks. The full-year shipment volume is expected to be between 800 million and 840 million cans.
Sep.03 by 2FIRSTS.ai
A joint operation by multiple departments in Brazil seized 20 boxes of illegal e-cigarettes worth about $90,000
A joint operation by multiple departments in Brazil seized 20 boxes of illegal e-cigarettes worth about $90,000
Brazilian federal police, border patrol, and military jointly seize 20 crates of illegal e-cigarettes in Altônia National Park.
Sep.18 by 2FIRSTS.ai
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
At the inaugural AFN, Dr. Rohan Sequeira and Dr. Alex Wodak emphasized that THR offers a science-based approach to reduce smoking-related harm—not merely as an alternative to cessation. They urged policymakers across Asia to reassess tobacco control and include non-combustible products in public health strategies. This article outlines the scientific foundation of THR, its regional challenges, and growth momentum.2Firsts provided in-depth coverage of the forum.
Sep.09
Related Topics
HEADLINE Company Regulation
Related Read
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
Smoore International's subsidiary, Transcend Biopharma, has its ANDA accepted by the FDA, potentially granting it 180 days of market exclusivity
2FIRSTS.ai
Smoore's 2025 first-half performance: Revenue rose 18.3% to 6.013 billion yuan, with self - brand revenue up 14.1% to 1.274 billion yuan
Smoore's 2025 first-half performance: Revenue rose 18.3% to 6.013 billion yuan, with self - brand revenue up 14.1% to 1.274 billion yuan
2FIRSTS.ai
Research Abstract｜Months After Flavored Tobacco Ban, More Than Half of Vape Shops in California Remain Noncompliant
Research Abstract｜Months After Flavored Tobacco Ban, More Than Half of Vape Shops in California Remain Noncompliant
2FIRSTS.ai
Company | Philip Morris CEO: Expected profit growth in 2025 will be the highest in over a decade, with ZYN US retail sales up 32%
Company | Philip Morris CEO: Expected profit growth in 2025 will be the highest in over a decade, with ZYN US retail sales up 32%
2FIRSTS.ai
A joint operation by multiple departments in Brazil seized 20 boxes of illegal e-cigarettes worth about $90,000
A joint operation by multiple departments in Brazil seized 20 boxes of illegal e-cigarettes worth about $90,000
2FIRSTS.ai
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
Experts Make the Case for THR in Asia-Pacific, as Demand, Science, and Industry Drive Its Growth
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2025 Shenzhen 2FIRSTS Technology Co.,Ltd. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland. For Chinese mainland users, please visit https://cn.2firsts.com
English
English
中文